Merus N.V. (MRUS) NASDAQ

90.00

+0(+0.00%)

Updated at January 02 09:30AM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Sven Ante Lundberg	Chief Executive Officer, President & Executive Director	1.24M	1963
Jan van de Winkel	CEO & Executive Director	0	N/A
Cornelis Adriaan de Kruif	Chief Technology Officer & Executive Vice President	380,471	1964
Fabian Zohren	Chief Medical Officer	637,930	1976
Gregory D. Perry	Chief Financial Officer	757,509	1960
Peter Silverman	EVice President, Company Secretary, Chief Operating Officer, General Counsel, Chief Intellectual Property Officer & Head of US Legal	895,170	1978
Cecilia Anna Wilhelmina Geuijen	Chief Scientific Officer & Senior Vice President	0	N/A
Harry Shuman	Chief Accounting Officer	0	N/A
Hennie Hoogenboom	Co-Founder and Scientific Advisor	0	N/A
Kathleen Farren	Director of IR & Corporate Communications Officer	0	N/A
Sherri Spear	Senior Vice President of Investor Relations & Strategic Communications	0	N/A

Name

Title

Pay

Year Born

Sven Ante Lundberg

Chief Executive Officer, President & Executive Director

1.24M

1963

Jan van de Winkel

CEO & Executive Director

N/A

Cornelis Adriaan de Kruif

Chief Technology Officer & Executive Vice President

380,471

1964

Fabian Zohren

Chief Medical Officer

637,930

1976

Gregory D. Perry

Chief Financial Officer

757,509

1960

Peter Silverman

EVice President, Company Secretary, Chief Operating Officer, General Counsel, Chief Intellectual Property Officer & Head of US Legal

895,170

1978

Cecilia Anna Wilhelmina Geuijen

Chief Scientific Officer & Senior Vice President

N/A

Harry Shuman

Chief Accounting Officer

N/A

Hennie Hoogenboom

Co-Founder and Scientific Advisor

N/A

Kathleen Farren

Director of IR & Corporate Communications Officer

N/A

Sherri Spear

Senior Vice President of Investor Relations & Strategic Communications

N/A

Description

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.